SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Ehtisham J, Altieri M, Salame E, Saloux E, Ollivier I, Hamon M. Coronary artery disease in orthotopic liver transplantation: pretransplant assessment and management. Liver Transpl 2010; 16: 550-557.
  • 2
    Carey WD, Dumot JA, Pimentel RR, Barnes DS, Hobbs RE, Henderson JM, et al. The prevalence of coronary artery disease in liver transplant candidates over age 50. Transplantation 1995; 59: 859-864.
  • 3
    Morris JJ, Hellman CL, Gawey BJ, Ramsay MA, Valek TR, Gunning TC, et al. Case 3-1995. Three patients requiring both coronary artery bypass surgery and orthotopic liver transplantation. J Cardiothorac Vasc Anesth 1995; 9: 322-332.
  • 4
    Donovan CL, Marcovitz PA, Punch JD, Bach DS, Brown KA, Lucey MR, Armstrong WF. Two-dimensional and dobutamine stress echocardiography in the preoperative assessment of patients with end-stage liver disease prior to orthotopic liver transplantation. Transplantation 1996; 61: 1180-1188.
  • 5
    Plotkin JS, Benitez RM, Kuo PC, Njoku MJ, Ridge LA, Lim JW, et al. Dobutamine stress echocardiography for preoperative cardiac risk stratification in patients undergoing orthotopic liver transplantation. Liver Transpl Surg 1998; 4: 253-257.
  • 6
    Tiukinhoy-Laing SD, Rossi JS, Bayram M, De Luca L, Gafoor S, Blei A, et al. Cardiac hemodynamic and coronary angiographic characteristics of patients being evaluated for liver transplantation. Am J Cardiol 2006; 98: 178-181.
  • 7
    Blei AT, Mazhar S, Davidson CJ, Flamm SL, Abecassis M, Gheorghiade M. Hemodynamic evaluation before liver transplantation—insights into the portal hypertensive syndrome. J Clin Gastroenterol 2007; 41( 3 Suppl): S323-S329.
  • 8
    Plotkin JS, Scott VL, Pinna A, Dobsch BP, De Wolf AM, Kang Y. Morbidity and mortality in patients with coronary artery disease undergoing orthotopic liver transplantation. Liver Transpl Surg 1996; 2: 426-430.
  • 9
    Diedrich DA, Findlay JY, Harrison BA, Rosen CB. Influence of coronary artery disease on outcomes after liver transplantation. Transplant Proc 2008; 40: 3554-3557.
  • 10
    Keeffe BG, Valantine H, Keeffe EB. Detection and treatment of coronary artery disease in liver transplant candidates. Liver Transpl 2001; 7: 755-761.
  • 11
    Bizouarn P, Ausseur A, Desseigne P, Le Teurnier Y, Nougarede B, Train M, Michaud JL. Early and late outcome after elective cardiac surgery in patients with cirrhosis. Ann Thorac Surg 1999; 67: 1334-1338.
  • 12
    Lisman T, Leebeek FW. Hemostatic alterations in liver disease: a review on pathophysiology, clinical consequences, and treatment. Dig Surg 2007; 24: 250-258.
  • 13
    Bosch J, Garcia-Pagan JC. Complications of cirrhosis. I. Portal hypertension. J Hepatol 2000; 32( 1 Suppl): 141-156.
  • 14
    Tobis J, Azarbal B, Slavin L. Assessment of intermediate severity coronary lesions in the catheterization laboratory. J Am Coll Cardiol 2007; 49: 839-848.
  • 15
    Smith SC Jr, Feldman TE, Hirshfeld JW Jr, Jacobs AK, Kern MJ, King SB III, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention—summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 2006; 113: 156-175.
  • 16
    Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined—a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction. J Am Coll Cardiol 2000; 36: 959-969.
  • 17
    Kushner FG, Hand M, Smith SC Jr, King SB III, Anderson JL, Antman EM, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2009; 120: 2271-2306.
  • 18
    Rao AK, Pratt C, Berke A, Jaffe A, Ockene I, Schreiber TL, et al. Thrombolysis in Myocardial Infarction (TIMI) trial—phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988; 11: 1-11.
  • 19
    Berkowitz SD, Sane DC, Sigmon KN, Shavender JH, Harrington RA, Tcheng JE, et al. Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) study group. J Am Coll Cardiol 1998; 32: 311-319.
  • 20
    Waksman R, King SB III, Douglas JS, Shen Y, Ewing H, Mueller L, et al. Predictors of groin complications after balloon and new-device coronary intervention. Am J Cardiol 1995; 75: 886-889.
  • 21
    Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464-470.
  • 22
    Ghobrial RM, Farmer DG, Baquerizo A, Colquhoun S, Rosen HR, Yersiz H, et al. Orthotopic liver transplantation for hepatitis C: outcome, effect of immunosuppression, and causes of retransplantation during an 8-year single-center experience. Ann Surg 1999; 229: 824-831.
  • 23
    Shaheen AA, Kaplan GG, Hubbard JN, Myers RP. Morbidity and mortality following coronary artery bypass graft surgery in patients with cirrhosis: a population-based study. Liver Int 2009; 29: 1141-1151.
  • 24
    Filsoufi F, Salzberg SP, Rahmanian PB, Schiano TD, Elsiesy H, Squire A, Adams DH. Early and late outcome of cardiac surgery in patients with liver cirrhosis. Liver Transpl 2007; 13: 990-995.
  • 25
    Axelrod D, Koffron A, Dewolf A, Baker A, Fryer J, Baker T, et al. Safety and efficacy of combined orthotopic liver transplantation and coronary artery bypass grafting. Liver Transpl 2004; 10: 1386-1390.
  • 26
    Benedetti E, Massad MG, Chami Y, Wiley T, Layden TJ. Is the presence of surgically treatable coronary artery disease a contraindication to liver transplantation? Clin Transplant 1999; 13( 1 Pt 1): 59-61.
  • 27
    Pillarisetti J, Patel P, Duthuluru S, Roberts J, Chen W, Genton R, et al. Cardiac catheterization in patients with end-stage liver disease: safety and outcomes. Catheter Cardiovasc Interv 2011; 77: 45-48.
  • 28
    Poldermans D, Schouten O, Vidakovic R, Bax JJ, Thomson IR, Hoeks SE, et al. A clinical randomized trial to evaluate the safety of a noninvasive approach in high-risk patients undergoing major vascular surgery: the DECREASE-V pilot study. J Am Coll Cardiol 2007; 49: 1763-1769.
  • 29
    Schouten O, van Kuijk JP, Flu WJ, Winkel TA, Welten GM, Boersma E, et al. Long-term outcome of prophylactic coronary revascularization in cardiac high-risk patients undergoing major vascular surgery (from the randomized DECREASE-V pilot study). Am J Cardiol 2009; 103: 897-901.